Abnormally expressed beta-amyloid affects bone metabolism

doi:10.12307/2022.613

Abstract

Abstract: BACKGROUND: Amyloid β exists widely in human tissues, and its abnormal expression is closely related to various chronic inflammatory diseases such as Alzheimer’s disease and osteoporosis. Studies have shown that amyloid β deposits in human vertebrae and femur and then causes bone destruction. However, the effect of low expression of amyloid β on bone metabolism remains unclear.
OBJECTIVE: To investigate the effect of overexpression and low expression of amyloid β on bone metabolism in mice.
METHODS: There were three groups: an APPswe+/+ group with APPswe+/+ transgenic mice aged 12 months with overexpression of amyloid β, a BACE-/- group with β-secretase cleaving enzyme-1 gene knockout mice with low expression of amyloid β, and a wild type group with wild type mice. Amyloid β deposition in bone tissue was observed by Congo red staining. Immunohistochemical staining was used to detect the distribution of amyloid precursor protein in bone tissue, and micro-computed tomography was used to study the difference of overall bone structure. Alkaline phosphatase staining and tartrate-resistant acid phosphatase staining were used to analyze the differences between bone formation and bone resorption.
RESULTS AND CONCLUSION: Compared with the wild type group, amyloid β deposition of cancellous bone and compact bone was increased in the APPswe+/+ group, and decreased in the BACE-/- group (P < 0.05). Compared with the wild type group, the expression of amyloid precursor protein in mouse cancellous bone was increased in the APPswe+/+ and BACE-/- groups. Compared with the wild type group, the bone mass and thickness of trabecular bone were decreased, and trabecular bone became thinner, sparse, disordered or fractured in the APPswe+/+ and BACE-/- groups. There was also abnormal bone formation and enhanced activity of osteoclasts in the APPswe+/+ and BACE-/- groups (P < 0.05). To conclude, overexpression or low expression of amyloid β can cause bone metabolism disorder and lead to bone loss. Abnormal lower expression of amyloid β caused by β-secretase cleaving enzyme-1 gene knockout can affect the expression of amyloid precursor protein in bone, and lead to an abnormal bone metabolism.

Key words: amyloid β, bone metabolism, β-secretase cleaving enzyme-1, amyloid precursor protein, bone destruction

CLC Number:

Li Fangyu, Xia Wenfang, Cui Shun. Abnormally expressed beta-amyloid affects bone metabolism[J]. Chinese Journal of Tissue Engineering Research, 2022, 26(20): 3152-3157.

Figures/Tables 5

References

[1] 孙红婷,宋艳荣. 楮实子提取物对APP /PS1小鼠学习记忆能力及对PI3K-C Ｒ EB-XBP1信号通路的影响[J]. 中国免疫学杂志,2019, 35(24):3021-3026.
[2] PENNEY J, RALVENIUS WT, TSAI L. Modeling Alzheimer’s disease with iPSC-derived brain cells. Mol Psychiatry. 2020;25(1):148-167.
[3] DENGLER-CRISH CM, ELEFTERIOU F. Shared mechanisms: osteoporosis and Alzheimer’s disease. 2019:1317-1318.
[4] CUI S, XIONG F, HONG Y, et al. APPswe/Aβ regulation of osteoclast activation and RAGE expression in an age-dependent manner. Bone Miner Res. 2011;26(5):1084-1098.
[5] XIA W, JUNG J, SHUN C, et al. Swedish mutant APP suppresses osteoblast differentiation and causes osteoporotic deficit, which are ameliorated by N-acetyl-L-cysteine. J Bone Miner Res. 2013;28(10): 2122-2135.
[6] MCLEOD J, CURTIS N, LEWIS HD, et al. γ‐Secretase‐dependent cleavage of amyloid precursor protein regulates osteoblast behavior. FASEB J. 2009;23(9): 2942-2955.
[7] LI S, LIU B, ZHANG L, et al. Amyloid beta peptide is elevated in osteoporotic bone tissues and enhances osteoclast function. Bone. 2014;61:164-175.
[8] IMBIMBO BP, WATLING M. Investigational BACE inhibitors for the treatment of Alzheimer’s disease. Expert Opin Investig Drugs. 2019; 28(11):967-975.
[9] TIWARI S, ATLURI V, KAUSHIK A, et al. Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine. 2019; 14:5541-5554.
[10] BERA S, CAMBLOR-PERUJO S, CALLEJA BE, et al. AP-2 reduces amyloidogenesis by promoting BACE1 trafficking and degradation in neurons. EMBO Rep. 2020;21(6):e47954.
[11] 邱伟, 连星烨. 唑来膦酸干预老年骨质疏松性股骨转子间骨折髋关节置换后患者骨密度、骨代谢标志物的2年随访[J]. 中国组织工程研究,2021,25(33):5265-5272.
[12] MACÍAS I, ALCORTA-SEVILLANO N, RODRÍGUEZ CI, et al. Osteoporosis and the Potential of Cell-Based Therapeutic Strategies. Int J Mol Sci. 2020;21(5):1653.
[13] ALZHEIMER’S ASSOCIATION. 2015 Alzheimer’s disease facts and figures. Alzheimers Dement. 2015;11(3):332-384.
[14] DOWNEY CL, YOUNG A, BURTON EF, et al. Dementia and osteoporosis in a geriatric population: Is there a common link? World J Orthop. 2017;8(5):412.
[15] STAPLEDON CJM, STAMENKOV R, CAPPAI R, et al. Relationships between the Bone Expression of Alzheimer’s Disease-Related Genes, Bone Remodelling Genes and Cortical Bone Structure in Neck of Femur Fracture. Calcif Tissue Int. 2021;108(5):610-621.
[16] NGUYEN PH, RAMAMOORTHY A, SAHOO BR, et al. Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer’s Disease, Parkinson’s Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis. Chem Rev. 2021;121(4):2545-2647.
[17] OTZEN D, RIEK R. Functional Amyloids. 2019:11.
[18] ROHER AE, ESH CL, KOKJOHN TA, et al. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer’s disease. Alzheimers Dement. 2009;5(1):18-29.
[19] YANG B, LI S, CHEN Z, et al. Amyloid β peptide promotes bone formation by regulating Wnt/β‐catenin signaling and the OPG/RANKL/RANK system. FASEB J. 2020;34(3):3583-3593.
[20] 李苗苗, 罗炯, 张庭然, 等. 骨质代谢与运动训练：骨重塑与骨细胞增殖[J]. 中国组织工程研究,2019,23(34):5544-5549.
[21] LIU H, LUO T, TAN J, et al. ‘Osteoimmunology’ Offers New Perspectives for the Treatment of Pathological Bone Loss. Curr Pharm Des. 2017; 23(41):6272-6278.
[22] NIE R, WU Z, NI J, et al. Porphyromonas gingivalis Infection Induces Amyloid-beta Accumulation in Monocytes/Macrophages. J Alzheimers Dis. 2019;72(2):479-494.
[23] PARK EK, JUNG HS, YANG HI, et al. Optimized THP-1 differentiation is required for the detection of responses to weak stimuli. Inflamm Res. 2007;56(1):45-50.
[24] LEE JW, NAM H, KIM LE, et al. TLR4 (toll-like receptor 4) activation suppresses autophagy through inhibition of FOXO3 and impairs phagocytic capacity of microglia. Autophagy. 2019;15(5):753-770.
[25] JIN HK, BAE JS, FURUYA S, et al. Amyloid beta-derived neuroplasticity in bone marrow-derived mesenchymal stem cells is mediated by NPY and 5-HT2B receptors via ERK1/2 signalling pathways. Cell Prolif. 2009;42(5):571-586.
[26] KORONYO-HAMAOUI M, SHEYN J, HAYDEN EY, et al. Peripherally derived angiotensin converting enzyme-enhanced macrophages alleviate Alzheimer-related disease. Brain. 2020;143(1):336-358.
[27] SHIN BK, KANG S, KIM DS, et al. Intermittent fasting protects against the deterioration of cognitive function, energy metabolism and dyslipidemia in Alzheimer’s disease-induced estrogen deficient rats. Exp Biol Med (Maywood). 2018;243(4):334-343.
[28] SIVAJI K, KANNAN RR, NANDHAGOPAL S, et al. Exogenous human beta amyloid peptide interferes osteogenesis through Sox9a in embryonic zebrafish. Mol Biol Rep. 2019;46(5):4975-4984.
[29] DANIELS MJ, RIVERS-AUTY J, SCHILLING T, et al. Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer’s disease in rodent models. Nat Commun. 2016;7:12504.
[30] WANG TH, JIANG Y, XIAO LP. Expression of amyloid beta-protein in bone tissue of APP/PS1 transgenic mouse. Zhonghua Yi Xue Za Zhi. 2013;93(1):65-68.
[31] SPÄNI C, SUTER T, DERUNGS R, et al. Reduced beta-amyloid pathology in an APP transgenic mouse model of Alzheimer’s disease lacking functional B and T cells. Acta Neuropathol Commun. 2015;3:71.
[32] CRUZ E, KUMAR S, YUAN L, et al. Intracellular amyloid beta expression leads to dysregulation of the mitogen-activated protein kinase and bone morphogenetic protein-2 signaling axis. PLoS One. 2018;13(2): e0191696.